IBDEI20D ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,32052,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,32052,1,3,0)
;;=3^Chlamydia (Culture +)
;;^UTILITY(U,$J,358.3,32052,1,4,0)
;;=4^A74.89
;;^UTILITY(U,$J,358.3,32052,2)
;;=^5000387
;;^UTILITY(U,$J,358.3,32053,0)
;;=Z11.8^^126^1644^16
;;^UTILITY(U,$J,358.3,32053,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,32053,1,3,0)
;;=3^Screen,Chlamydia
;;^UTILITY(U,$J,358.3,32053,1,4,0)
;;=4^Z11.8
;;^UTILITY(U,$J,358.3,32053,2)
;;=^5062677
;;^UTILITY(U,$J,358.3,32054,0)
;;=A56.02^^126^1644^4
;;^UTILITY(U,$J,358.3,32054,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,32054,1,3,0)
;;=3^Chlamydial Vulvovaginitis
;;^UTILITY(U,$J,358.3,32054,1,4,0)
;;=4^A56.02
;;^UTILITY(U,$J,358.3,32054,2)
;;=^5000340
;;^UTILITY(U,$J,358.3,32055,0)
;;=Z20.2^^126^1644^5
;;^UTILITY(U,$J,358.3,32055,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,32055,1,3,0)
;;=3^Contact with/Exposure to Infection,Sexual Mode of Transmission
;;^UTILITY(U,$J,358.3,32055,1,4,0)
;;=4^Z20.2
;;^UTILITY(U,$J,358.3,32055,2)
;;=^5062764
;;^UTILITY(U,$J,358.3,32056,0)
;;=N71.9^^126^1644^6
;;^UTILITY(U,$J,358.3,32056,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,32056,1,3,0)
;;=3^Endometritis
;;^UTILITY(U,$J,358.3,32056,1,4,0)
;;=4^N71.9
;;^UTILITY(U,$J,358.3,32056,2)
;;=^5015811
;;^UTILITY(U,$J,358.3,32057,0)
;;=A54.00^^126^1644^9
;;^UTILITY(U,$J,358.3,32057,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,32057,1,3,0)
;;=3^Gonorrhea (Culture +),Lower GU Tract
;;^UTILITY(U,$J,358.3,32057,1,4,0)
;;=4^A54.00
;;^UTILITY(U,$J,358.3,32057,2)
;;=^5000311
;;^UTILITY(U,$J,358.3,32058,0)
;;=Z11.3^^126^1644^17
;;^UTILITY(U,$J,358.3,32058,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,32058,1,3,0)
;;=3^Screen,Gonorrhea
;;^UTILITY(U,$J,358.3,32058,1,4,0)
;;=4^Z11.3
;;^UTILITY(U,$J,358.3,32058,2)
;;=^5062672
;;^UTILITY(U,$J,358.3,32059,0)
;;=A60.04^^126^1644^10
;;^UTILITY(U,$J,358.3,32059,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,32059,1,3,0)
;;=3^Herpesviral Vulvovaginitis
;;^UTILITY(U,$J,358.3,32059,1,4,0)
;;=4^A60.04
;;^UTILITY(U,$J,358.3,32059,2)
;;=^5000356
;;^UTILITY(U,$J,358.3,32060,0)
;;=N89.8^^126^1644^11
;;^UTILITY(U,$J,358.3,32060,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,32060,1,3,0)
;;=3^Leukorrhea
;;^UTILITY(U,$J,358.3,32060,1,4,0)
;;=4^N89.8
;;^UTILITY(U,$J,358.3,32060,2)
;;=^88111
;;^UTILITY(U,$J,358.3,32061,0)
;;=N73.0^^126^1644^12
;;^UTILITY(U,$J,358.3,32061,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,32061,1,3,0)
;;=3^Pelvic Cellulitis
;;^UTILITY(U,$J,358.3,32061,1,4,0)
;;=4^N73.0
;;^UTILITY(U,$J,358.3,32061,2)
;;=^270467
;;^UTILITY(U,$J,358.3,32062,0)
;;=N76.1^^126^1644^20
;;^UTILITY(U,$J,358.3,32062,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,32062,1,3,0)
;;=3^Vaginitis,Subacute and Chronic
;;^UTILITY(U,$J,358.3,32062,1,4,0)
;;=4^N76.1
;;^UTILITY(U,$J,358.3,32062,2)
;;=^5015827
;;^UTILITY(U,$J,358.3,32063,0)
;;=A53.9^^126^1644^18
;;^UTILITY(U,$J,358.3,32063,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,32063,1,3,0)
;;=3^Syphilis
;;^UTILITY(U,$J,358.3,32063,1,4,0)
;;=4^A53.9
;;^UTILITY(U,$J,358.3,32063,2)
;;=^5000310
;;^UTILITY(U,$J,358.3,32064,0)
;;=A59.01^^126^1644^19
;;^UTILITY(U,$J,358.3,32064,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,32064,1,3,0)
;;=3^Trichomonal Vulvovaginitis
;;^UTILITY(U,$J,358.3,32064,1,4,0)
;;=4^A59.01
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI20D 3748 printed Sep 23, 2025@19:55:20 Page 2
IBDEI20D ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,32052,1,0)
+2 ;;=^358.31IA^4^2
+3 ;;^UTILITY(U,$J,358.3,32052,1,3,0)
+4 ;;=3^Chlamydia (Culture +)
+5 ;;^UTILITY(U,$J,358.3,32052,1,4,0)
+6 ;;=4^A74.89
+7 ;;^UTILITY(U,$J,358.3,32052,2)
+8 ;;=^5000387
+9 ;;^UTILITY(U,$J,358.3,32053,0)
+10 ;;=Z11.8^^126^1644^16
+11 ;;^UTILITY(U,$J,358.3,32053,1,0)
+12 ;;=^358.31IA^4^2
+13 ;;^UTILITY(U,$J,358.3,32053,1,3,0)
+14 ;;=3^Screen,Chlamydia
+15 ;;^UTILITY(U,$J,358.3,32053,1,4,0)
+16 ;;=4^Z11.8
+17 ;;^UTILITY(U,$J,358.3,32053,2)
+18 ;;=^5062677
+19 ;;^UTILITY(U,$J,358.3,32054,0)
+20 ;;=A56.02^^126^1644^4
+21 ;;^UTILITY(U,$J,358.3,32054,1,0)
+22 ;;=^358.31IA^4^2
+23 ;;^UTILITY(U,$J,358.3,32054,1,3,0)
+24 ;;=3^Chlamydial Vulvovaginitis
+25 ;;^UTILITY(U,$J,358.3,32054,1,4,0)
+26 ;;=4^A56.02
+27 ;;^UTILITY(U,$J,358.3,32054,2)
+28 ;;=^5000340
+29 ;;^UTILITY(U,$J,358.3,32055,0)
+30 ;;=Z20.2^^126^1644^5
+31 ;;^UTILITY(U,$J,358.3,32055,1,0)
+32 ;;=^358.31IA^4^2
+33 ;;^UTILITY(U,$J,358.3,32055,1,3,0)
+34 ;;=3^Contact with/Exposure to Infection,Sexual Mode of Transmission
+35 ;;^UTILITY(U,$J,358.3,32055,1,4,0)
+36 ;;=4^Z20.2
+37 ;;^UTILITY(U,$J,358.3,32055,2)
+38 ;;=^5062764
+39 ;;^UTILITY(U,$J,358.3,32056,0)
+40 ;;=N71.9^^126^1644^6
+41 ;;^UTILITY(U,$J,358.3,32056,1,0)
+42 ;;=^358.31IA^4^2
+43 ;;^UTILITY(U,$J,358.3,32056,1,3,0)
+44 ;;=3^Endometritis
+45 ;;^UTILITY(U,$J,358.3,32056,1,4,0)
+46 ;;=4^N71.9
+47 ;;^UTILITY(U,$J,358.3,32056,2)
+48 ;;=^5015811
+49 ;;^UTILITY(U,$J,358.3,32057,0)
+50 ;;=A54.00^^126^1644^9
+51 ;;^UTILITY(U,$J,358.3,32057,1,0)
+52 ;;=^358.31IA^4^2
+53 ;;^UTILITY(U,$J,358.3,32057,1,3,0)
+54 ;;=3^Gonorrhea (Culture +),Lower GU Tract
+55 ;;^UTILITY(U,$J,358.3,32057,1,4,0)
+56 ;;=4^A54.00
+57 ;;^UTILITY(U,$J,358.3,32057,2)
+58 ;;=^5000311
+59 ;;^UTILITY(U,$J,358.3,32058,0)
+60 ;;=Z11.3^^126^1644^17
+61 ;;^UTILITY(U,$J,358.3,32058,1,0)
+62 ;;=^358.31IA^4^2
+63 ;;^UTILITY(U,$J,358.3,32058,1,3,0)
+64 ;;=3^Screen,Gonorrhea
+65 ;;^UTILITY(U,$J,358.3,32058,1,4,0)
+66 ;;=4^Z11.3
+67 ;;^UTILITY(U,$J,358.3,32058,2)
+68 ;;=^5062672
+69 ;;^UTILITY(U,$J,358.3,32059,0)
+70 ;;=A60.04^^126^1644^10
+71 ;;^UTILITY(U,$J,358.3,32059,1,0)
+72 ;;=^358.31IA^4^2
+73 ;;^UTILITY(U,$J,358.3,32059,1,3,0)
+74 ;;=3^Herpesviral Vulvovaginitis
+75 ;;^UTILITY(U,$J,358.3,32059,1,4,0)
+76 ;;=4^A60.04
+77 ;;^UTILITY(U,$J,358.3,32059,2)
+78 ;;=^5000356
+79 ;;^UTILITY(U,$J,358.3,32060,0)
+80 ;;=N89.8^^126^1644^11
+81 ;;^UTILITY(U,$J,358.3,32060,1,0)
+82 ;;=^358.31IA^4^2
+83 ;;^UTILITY(U,$J,358.3,32060,1,3,0)
+84 ;;=3^Leukorrhea
+85 ;;^UTILITY(U,$J,358.3,32060,1,4,0)
+86 ;;=4^N89.8
+87 ;;^UTILITY(U,$J,358.3,32060,2)
+88 ;;=^88111
+89 ;;^UTILITY(U,$J,358.3,32061,0)
+90 ;;=N73.0^^126^1644^12
+91 ;;^UTILITY(U,$J,358.3,32061,1,0)
+92 ;;=^358.31IA^4^2
+93 ;;^UTILITY(U,$J,358.3,32061,1,3,0)
+94 ;;=3^Pelvic Cellulitis
+95 ;;^UTILITY(U,$J,358.3,32061,1,4,0)
+96 ;;=4^N73.0
+97 ;;^UTILITY(U,$J,358.3,32061,2)
+98 ;;=^270467
+99 ;;^UTILITY(U,$J,358.3,32062,0)
+100 ;;=N76.1^^126^1644^20
+101 ;;^UTILITY(U,$J,358.3,32062,1,0)
+102 ;;=^358.31IA^4^2
+103 ;;^UTILITY(U,$J,358.3,32062,1,3,0)
+104 ;;=3^Vaginitis,Subacute and Chronic
+105 ;;^UTILITY(U,$J,358.3,32062,1,4,0)
+106 ;;=4^N76.1
+107 ;;^UTILITY(U,$J,358.3,32062,2)
+108 ;;=^5015827
+109 ;;^UTILITY(U,$J,358.3,32063,0)
+110 ;;=A53.9^^126^1644^18
+111 ;;^UTILITY(U,$J,358.3,32063,1,0)
+112 ;;=^358.31IA^4^2
+113 ;;^UTILITY(U,$J,358.3,32063,1,3,0)
+114 ;;=3^Syphilis
+115 ;;^UTILITY(U,$J,358.3,32063,1,4,0)
+116 ;;=4^A53.9
+117 ;;^UTILITY(U,$J,358.3,32063,2)
+118 ;;=^5000310
+119 ;;^UTILITY(U,$J,358.3,32064,0)
+120 ;;=A59.01^^126^1644^19
+121 ;;^UTILITY(U,$J,358.3,32064,1,0)
+122 ;;=^358.31IA^4^2
+123 ;;^UTILITY(U,$J,358.3,32064,1,3,0)
+124 ;;=3^Trichomonal Vulvovaginitis
+125 ;;^UTILITY(U,$J,358.3,32064,1,4,0)
+126 ;;=4^A59.01
